Final Results of Cabozantinib plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma - Darren Feldman
Darren Feldman
Darren Feldman presents final results of a phase 2 single-center trial of cabozantinib plus nivolumab in non-clear cell RCC to Tian Zhang, now including 60 total patients and approximately 50 months of median follow-up for survivors.
